[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"EuroCityClinic LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100602939","phase-2-efficacy-and-safety-of-anti-pd-1pd-l1-antibodies-in-combination-with-bevacizumab-and-metronomic-cyclophosphamide-in-patients-with-non-small-cell-lung-cancer-and-cutaneous-melanoma-previously-treated-with-immune-checkpoint-blockade-100602939",false,"NCT07130032","Efficacy And Safety Of Anti-PD-1\u002FPD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade","A Trial To Compare Efficacy And Safety Of Anti-PD-1\u002FPD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade","reICB","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Provide written informed consent\n* Age ≥ 18 years\n* Histologically confirmed diagnosis of NSCLC and cutaneous melanoma with distant metastases.\n* No mutations in the EGFR gene, ALK, ROS1, RET gene translocations (in case of NSCLC).\n* For NSCLC: the individuals had previously received anti-PD-(L)1 antibodies in combination with platinum-containing chemotherapy either in the first line or sequentially in the first and second lines for the treatment of metastatic disease.\n* For NSCLC: the individuals had previously received anti-PD-(L)1 antibodies for \\>6 months and experienced disease progression.\n* For cutaneous melanoma: the individuals had previously received anti-PD-1 antibodies either in combination with or without anti-CTLA4 therapy for metastatic disease. If the patient had the BRAF V600 mutation, they were also treated with BRAF and MEK inhibitors.\n* For cutaneous melanoma: the patient has previously received anti-PD-1 antibodies with or without anti-CTLA4 therapy for metastatic disease for \\>6 months and experienced disease progression\n\nExclusion Criteria:\n\n* Presence of clinically significant cardiovascular disease: severe or unstable ischemic heart disease, history of myocardial infarction, New York Heart Association Class III\u002FIV congestive heart failure, ventricular arrhythmias.\n* Stroke and\u002For transient ischemic attack within 6 months prior to screening;\n* Uncontrolled hypertension\n* History of previous malignancies except non-melanoma skin cancers, or in situ cervical or breast cancer unless a complete remission was achieved at least 2 years prior to randomization AND no additional therapy is required during the study period. Patients having hepatic involvement of cancer should be excluded as per investigator assessment.\n* Patients with CNS metastases are eligible only if the metastases are adequately treated.\n* Absolute neutrophil count (ANC) \\\u003C1.5×109\u002FL, platelet count \\\u003C100×109\u002FL, or hemoglobin \\\u003C9.0 g\u002FdL.\n* Serum total bilirubin \\>1.5 × the upper limit of normal (ULN). Participants with Gilbert syndrome, bilirubin \\\u003C2 X ULN, and normal AST\u002FALT are eligible;\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 × ULN;\n* Serum creatinine \\>1.5 × ULN.\n* History of a thromboembolic event\n* Presence of any allergic reactions to components of the study drugs\n* Concomitant medications with a known risk of causing QT prolongation and\u002For Torsades de Pointes.\n* Any parallel anti-cancer systemic therapy, radiation therapy\n* Women who are pregnant or lactating;\n* Presence of unresolved adverse events of grade 2 or higher toxicity, according to CTCAE v5.0 criteria, from prior therapy (except for alopecia or neurotoxicity grade≤2).\n* Any other serious or uncontrolled medical disorder, active infection, physical examination finding, laboratory finding, altered mental status, or psychiatric condition that, in the opinion of the investigator, would limit a patient's ability to comply with the study requirements, substantially increase risk to the patient, or impact the interpretability of study results.","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study will evaluate efficacy and safety of anti-PD-1\u002FPD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously treated with immune checkpoint blockade (ICB). The hypotheses of this study are that a combination of ICB, cyclophosphamide, and bevacizumab prolongs progression-free survival and overall survival, and also increases rates of objective responses and disease control.",[27,28],"Metastatic Non-small Cell Lung Cancer (NSCLC)","Metastatic Cutaneous Melanoma",[30,31,32,33,34],"Metastatic non-small cell lung cancer","Metastatic cutaneous melanoma","Immune checkpoint inhibitor","Bevacizumab","Metronomic cyclophosphamide","RECRUITING","2025-08-14",{"date":38,"type":39},"2025-08-19","ACTUAL",{"date":36,"type":39},{"date":42,"type":21},"2027-12",{"name":44,"class":45},"EuroCityClinic LLC","NETWORK",""]